

## ASH 2022 NHLBI Research Presentations

### *Friday, December 9*

#### **Scientific Workshop: Stem Cells**

##### **Niche-Derived Semaphorin 4A Prevents Functional Loss of Myeloid-Biased HSC during Inflammation and Aging**

Lev Silberstein, M.D., Ph.D.

2:42–3:45 p.m. CT

Room not yet listed

#### **Scientific Workshop: Stem Cells**

##### **Sleep Exerts Lasting Effects on Hematopoietic Stem Cell Function and Diversity**

Cameron McAlpine, Ph.D.

2:42–3:45 p.m. CT

Room not yet listed

#### **Scientific Workshop: Signaling and Developmental Hematopoiesis**

##### **Deconstructing Inflammatory Dynamics during Hematopoietic Stem Cell Development**

Raquel Espin Palazon, Ph.D.

3:35–4:15 p.m. CT

Room not yet listed

### *Saturday, December 10*

#### **Session: 114. Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Novel Therapies**

##### **7: Impact of Arginine Therapy on Clinical Outcomes, Mitochondrial Function and Oxidative Stress in Children with Sickle Cell Disease Hospitalized with Vasoocclusive Pain Episodes: A Randomized Controlled Trial**

Claudia Morris, M.D.

9:30 a.m. CT

Room 391-392

#### **Scientific Program: Aplastic anemia, dysimmunity, and mutant clones**

##### **Immune deregulation in aplastic anemia**

Neal Young, M.D.

9:30–10:45 a.m. CT

Room 288-290

#### **Session: 401. Blood Transfusion: Molecular Mechanisms and Novel Therapies**

##### **32: Antibody-Mediated Antigen Loss Can Switch an Augmented Immune Response to Antibody-Mediated Immunosuppression**

Ryan Jajosky, M.D.

9:45 a.m. CT

Room 393-396

**Session: 636. Myelodysplastic Syndromes—Basic and Translational: Clonal Trajectories and Novel Therapies**

**86: Clonal Trajectories and Therapeutic Targeting of High-Risk SF3B1-Mutant Myelodysplastic Syndromes**

Martina Sarchi, M.D.

9:45 a.m. CT

Room 260-262

**Session: 401. Blood Transfusion: Molecular Mechanisms and Novel Therapies**

**33: Reticulocytes Are an Unappreciated Risk Factor for RBC Alloimmunization at the Donor and Recipient Levels**

Krystalyn Hudson, Ph.D.

10 a.m. CT

Room 393-396

**Session: 201. Granulocytes, Monocytes, and Macrophages II**

**16: Ongoing Production of Tissue-Resident Macrophages from Hematopoietic Stem Cells in Healthy Adult Macaques**

Chuanfeng Wu, M.D., Ph.D.

10:15 a.m. CT

Room not yet listed

**Session: 401. Blood Transfusion: Molecular Mechanisms and Novel Therapies**

**34: Predictors, Risk Factors and Outcomes of Patients with SAA with Anti-HLA Class I Antibodies Treated with Immunosuppressive Therapy**

Jibrán Durrani, M.D.

10:15 a.m. CT

Room 393-396

**Session: 401. Blood Transfusion: Molecular Mechanisms and Novel Therapies**

**35: Blood Group A Enhances SARS-CoV-2 Infection**

Shang-Chuen Wu, Ph.D.

10:30 a.m. CT

Room 393-396

**Session: 331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological I**

**138: Silent Cerebral Infarction during Immune TTP Remission – Prevalence, Predictors and Impact on Cognition**

Shruti Chaturvedi, M.B.B.S.

12–1:30 p.m. CT

Great Hall A/D

**Session: 331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological I**

**135 Arginine Methylation on ADAMTS13 By Protein Arginine Methyltransferase 1 (PRMT1) Affects ADAMTS13 Secretion and Proteolytic Activity**

Szumam Liu, Ph.D.

12:30 p.m. CT  
Room 275-277

**Education: Late Effects of Curative Therapy for Sickle Cell Disease  
Knowledge to Date on Secondary Malignancy**

Courtney Fitzhugh, M.D.  
2-3:15 p.m. CT  
Hall E

**Session: 113. Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Cognitive Deficit,  
Pain, and Inflammation in Sickle Cell Disease: What We Learned from Mouse Models**

**175: Neuroinflammation Underlies the Development of Social Stress Induced Cognitive Deficit in  
Sickle Cell Disease**

Oluwabukola Gbotosho, Ph.D.  
2 – 3:30 p.m. CT  
Room 275-277

**Session: 508. Bone Marrow Failure: Acquired: Biology**

**193 JAK 1/2 Inhibition Preserves Hematopoietic Progenitor and Stem Cells, Prevents Aplasia, Inhibits  
Pro-Inflammatory Cytokines, and Prolongs Survival in Murine Immune Bone Marrow Failure**

Emma M. Groarke, M.D.  
2 p.m. CT  
Room 260-262

**Session: 113. Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Cognitive Deficit,  
Pain, and Inflammation in Sickle Cell Disease: What We Learned from Mouse Models**

**176: Microbial Metabolites Target Histone Deacetylases to Trigger Vascular Inflammation in Sickle Cell  
Disease**

Lidiane Torres, Ph.D.  
2:15 p.m. CT  
Room 275-277

**Session: 114. Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Hydroxyurea  
Treatment**

**182: Hydroxyurea with Dose-Escalation to Reduce Primary Stroke Risk in Children with Sickle Cell  
Anemia in Tanzania: Primary Results of the Sphere Trial**

Emmanuela Ambrose, M.D.  
2:15 p.m. CT  
Room 278-282

**Session: 113. Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Cognitive Deficit,  
Pain, and Inflammation in Sickle Cell Disease: What We Learned from Mouse Models**

**176: Microbial Metabolites Target Histone Deacetylases to Trigger Vascular Inflammation in Sickle Cell  
Disease**

Huihui Li, Ph.D.  
2:45 p.m. CT  
Room 275-277

**Session: 508. Bone Marrow Failure: Acquired: Biology**  
**197: The Role of Heterozygous Variants in SAMD9/9L and Recessive Bone Marrow Failure-Related Genes in Adults with Severe Aplastic Anemia**

Dalton Hironaka, B.A.

3:00 p.m. CT

Room 260-262

**Session: 113. Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Cognitive Deficit, Pain, and Inflammation in Sickle Cell Disease: What We Learned from Mouse Models**

**180: Cold Exposure Induces Vaso-Occlusion and Hyperalgesia in Mice with Sickle Cell Disease That Is Dependent on Complement Activation**

Zalaya Ivy, M.D., M.S.

3:15 p.m. CT

Room 275-277

**Session: 114. Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Hydroxyurea Treatment**

**186: Loss of Cyb5R3 Function Silences Fetal Hemoglobin and Hematocrit Responses to Hydroxyurea in Patients with Sickle Cell Anemia**

Katherine Wood, Ph.D.

3:15 p.m. CT

Room 278- 282

**Session: 101. Red Cells and Erythropoiesis, Excluding Iron I**

**285: The Molecular Pathophysiology of Ineffective Erythropoiesis at Single Cell Resolution**

Raymond Doty, Ph.D.

4:30 p.m. CT

Room 391-392

**Session: 602. Myeloid Oncogenesis: Basic: Chromatin Organization and Metabolism**

**297: Nuclear Phase Separation Directs HOX Expression in Acute Myeloid Leukemia**

Gandhar Datar, B.S.

4:30 p.m. CT

Room 293-294

**Session: 101. Red Cells and Erythropoiesis, Excluding Iron I**

**286: Anemia-Activated Cis Regulatory Requirements for Erythroid Regeneration**

Yichao Zhou

4:45 p.m. CT

Room 391-392

**Session: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Identification of Novel**

**329 The High Mobility Group A1 Chromatin Regulator Drives Immune Evasion during MPN Progression By Repressing Genes Involved in Antigen Presentation**

Joseph Kim

5 p.m. CT

Room 275-277

**Sunday, December 11**

**Session: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Molecular Consequences of MPN Driver and Co-mutations**

**451: Type 2 but Not Type 1 Calreticulin Mutants Exhibit Loss of Chaperone Function Due to C-Terminal Structural Interference, and Bind to Wild Type Calreticulin in a Dominant Negative Manner**

Nicole Arellano, B.A.

9:30 a.m. CT

Room 275-277

**Education: Sessions on malignant hematology acute myeloid leukemia: Improving outcomes in challenging subsets**

**Achieving MRD Negativity in AML: How Important Is This and How Do We Get There?**

Dr. Chris Hourigan

9:30–10:45 a.m. CT

Great Hall B/C

**Session: 113. Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Targeting the Red Blood Cell: Novel Therapeutic Approaches in Sickle Cell Disease**

**391 AG-946 Normalizes Glycolysis and Improves Red Cell Indices in a Humanized Sickle Cell Mouse Model**

Rohitash Jamwal, Ph.D.

9:30 a.m. CT

Room not listed yet

**Session: 509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: From Biology to Therapeutics**

**409: Regulated Expression of GATA1 As a Gene Therapy Cure for Diamond-Blackfan Anemia**

Richard Voit, M.D., Ph.D.

9:30 a.m. CT

Room 260-262

**Session: 701. Experimental Transplantation: Basic and Translational: Novel Mechanisms of Acute and Chronic Graft-versus-Host Disease**

**475 Donor-Derived Amphiregulin Drives CD4+ T Cell Expansion and Promotes Tissue Pathology after Experimental Allogeneic BMT**

Takahiro Ito, M.D.

9:30 a.m. CT

Room not listed yet

**Session: 321. Coagulation and Fibrinolysis: Basic and Translational I**

**398: Inhibiting Activated Protein C Cleavage of Factor VIII for Hemophilia a Gene Therapy**

Anna Sternberg, Ph.D.

9:45 a.m. CT

Room 293-294

**Session: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Molecular Consequences of MPN Driver and Co-mutations**

**452: Mutant Srsf2 Diminishes Jak2V617F-Induced Erythrocytosis in Mice and Is Associated with Lower Hemoglobin in Patients with Chronic Phase JAK2-Mutant MPN**

Anna Marneth, Ph.D.

9:45 a.m. CT

Room 275-277

**Session: 113. Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Targeting the Red Blood Cell: Novel Therapeutic Approaches in Sickle Cell Disease**

**393 Pklr Variants Associated with Acute Pain in Sickle Cell Disease Influence ATP Concentrations in Red Blood Cells**

Xunde Wang, Ph.D.

10 a.m. CT

Room 343-345

**Session: 321. Coagulation and Fibrinolysis: Basic and Translational I**

**399: Antigen Trafficking and Possibly Intrinsic Immunostimulatory Properties Shape High Immunogenicity of Factor VIII**

Radoslaw Kaczmarek, Ph.D.

10 a.m. CT

Room 293-294

**Session: 503. Clonal Hematopoiesis, Aging and Inflammation: Insights from Animal Models**

**405: The Impact of Dnmt3a or Tet2 CH on Alzheimer's Disease in a Murine Model**

Trisha Wathan

10 a.m. CT

Room 271-273

**Session: 113. Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Targeting the Red Blood Cell: Novel Therapeutic Approaches in Sickle Cell Disease**

**394: Preclinical Development and Screening of a Quinone-Nitroalkene Molecule for Sickle Cell Anemia**

Fabliha Chowdhury, M.Sc.

10:15 a.m. CT

Room 343-345

**Session: 904. Outcomes Research—Non-Malignant Conditions: Classical Hematology: From Horses to Zebras**

**508 Fatigue and Cognition During Remission in Adults with Immune Thrombotic Thrombocytopenic Purpura**

Deirdra Terrell, Ph.D.

10:15 a.m. CT

Room not yet listed

**Session: 321. Coagulation and Fibrinolysis: Basic and Translational I**

**401: Coagulation Factor XII Is Activated Via Noncanonical Binding to Platelet Integrin  $\alpha$ IIb $\beta$ 3**

Pavan Bendapudi, M.D.

10:30 a.m. CT

Room 293-294

**Session: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Molecular Consequences of MPN Driver and Co-mutations**

**455: Transcriptional and Metabolic Profiling Reveals Alpha-Ketoglutarate As a Novel Mediator of Aberrant Platelet Activity and Inflammation in Myeloproliferative Neoplasms**

Fan He, Ph.D.

10:30 a.m. CT

Room 275-277

**Session: 701. Experimental Transplantation: Basic and Translational: Novel Mechanisms of Acute and Chronic Graft-versus-Host Disease**

**479 The DNA-Sensor AIM2 Promotes BCR-Activated B Cells in Chronic Graft-Versus-Host-Disease**

Jonathan Visentin, Pharm.D., Ph.D.

10:30 a.m. CT

Room not yet listed

**Session: 113. Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Targeting the Red Blood Cell: Novel Therapeutic Approaches in Sickle Cell Disease**

**396: Prolonged Combinatorial Pharmacological Therapy Targeting the Epigenome Increases Fetal Hemoglobin to Clinically Relevant Levels in Normal, Nonanemic Baboons**

Donald Lavelle, Ph.D.

10:45 a.m. CT

Room 343-345

**Session: 509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: From Biology to Therapeutics**

**414 Pathogenic RUNX1 C-Terminal Truncation Mutations Contribute to Differentiation Block and Result in Unique Changes in Transcription and Chromatin Organization**

Nathan Jayne, B.Sc.

10:45 a.m. CT

Room 260-262

**Session: 627. Aggressive Lymphomas: Clinical and Epidemiological: Rare Populations**

**450: T-Cell Prolymphocytic Leukemia: Trends in Overall Survival Demonstrate Marginal Improvement over Time and Minimal Benefit with Currently Available Treatments**

Victoria Vardell, M.D.

10:45 a.m. CT

La Nouvelle Orleans Ballroom C

**Session: 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Cancer-associated Thrombosis: Risk Stratification, Prevention, and Treatment**

**518: Factor XI Inhibition for the Prevention of Catheter-Associated Thrombosis in Cancer Patients Undergoing Central Line Placement: A Phase 2 Clinical Trial**

Michael Pfeffer, M.B.B.S.

12:15 p.m. CT

Room 291-292

**Session: 602. Myeloid Oncogenesis: Basic: Epigenetics and Transcriptional Regulation**  
**532: Functional Characterization of Cooperating MGA Deletions in RUNX1::RUNX1T1 Acute Myeloid Leukemia**

Melvin Thomas, Ph.D.  
12:45 p.m. CT  
Room 275-277

**Session: 637. Myelodysplastic Syndromes – Clinical and Epidemiological IV**  
**562: Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A National Analysis of Overall Survival and Demographic Features**

Victoria Vardell, M.D.  
12:45 p.m. CT  
Room 265-268

**Session: 506. Bone Marrow Microenvironment: Contribution of Immune Signaling to the Microenvironment**  
**528: Jagged1+ Myeloid-Derived Suppressor Cells Are Required for Recovery of the Hematopoietic Bone Marrow Niche after Myelosuppression**

Kostandin Pajcini, Ph.D.  
1:45 p.m. CT  
Room 260-262

**Session: Plenary Scientific Session**

**5 C1 Inhibitor Deficiency Results in Increased Activation of Coagulation and Enhanced Venous Thrombosis**

Steven P Grover, Ph.D.  
2-4 p.m. CT  
Hall E

**Session: 201. Granulocytes, Monocytes, and Macrophages I**

**583: A Noncoding Germline Variant Creates a Gain-of-Function De Novo Enhancer That up-Regulates IL5 Transcription to Cause Familial Hypereosinophilia, Revealing a Previously Undescribed Mechanism for Human Disease**

Jung-Hyun Kim, Ph.D.  
4:30 p.m. CT  
Room 391-392

**Session: 322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Von Willebrand Disease and Other**

**590: Multicenter, Randomized Crossover Trial Comparing Recombinant Von Willebrand Factor and Tranexamic Acid for Heavy Menstrual Bleeding in Von Willebrand Disease**

Margaret Ragni, M.D., M.P.H.  
4:45 p.m. CT  
Room 288-290

**Session: 613. Acute Myeloid Leukemias: Clinical and Epidemiological: Genomic Determinants of Prognosis in Patients with Acute Myeloid Leukemia**



**597 Prognostic Impact of Secondary Versus De Novo Ontogeny in Acute Myeloid Leukemia (AML) Is Predominantly Accounted for By the European Leukemianet (ELN) 2022 Risk Classification**

Michael J. Hochman, M.D.

5 p.m. CT

Room not yet listed

**Session: 201. Granulocytes, Monocytes, and Macrophages I**

**586: Aggregation of Enveloped Viruses By Platelet Factor 4 (PF4) and Neutrophil Extracellular Traps (NETs): Implications for the Anti-Viral Properties of NETs**

Kandace Gollomp, M.D.

5:15 p.m. CT

Room 391-392

**Session: 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Longer Term Response, TFR, Pregnancy, and Disparities**

**624: Racial and Ethnic Disparities in Survival Outcomes in Chronic Myeloid Leukemia**

Catherine Sobieski, M.D.

5:45 p.m. CT

Room 388-390

***Monday, December 12***

**E. Donnal Thomas Lecture and Prize**

**The Long and Winding Road to Clinically Effective Graft-versus-Host Disease (GVHD) Therapeutics**

Bruce R. Blazar, M.D.

9–10 a.m. CT

Hall E

**Session: 301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational:**

**Thrombosis and the Endothelium**

**685: TMEM16E Regulates Endothelial Cell Procoagulant Activity and Thrombosis**

Alec Schmaier, M.D., Ph.D.

10:30 a.m. CT

Room 293-294

**Scientific Program: Childhood Red Cell Disorders: Embracing Technology to Improve How We Manage Challenging Anemias**

**New Technologies for Assessment of Anemia and Other Hematologic Disorders in Resource Limited Settings**

Wilbur Lam, M.D., Ph.D.

10:30–11:45 a.m. CT

Room 343-345

**Session: 321. Coagulation and Fibrinolysis: Basic and Translational II**

**692: X-Ray Structure of Thrombin Bound to a Heterobifunctional Aptamer-Drug Conjugate Reveals the Mechanistic Basis for a Novel Tethered Inhibition Strategy**

Shekar Kumar, Ph.D.

10:45 a.m. CT

Room 291-292

**Session: 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Delineating Immunity from Mice to Humans**

**681: Pediatric Evans Syndrome Displays Broad Immune Dysregulation Characterized By Extra-Follicular B-Cell Responses and Unique Autoantibody Repertoire**

Deepak Kumar, Ph.D.

11 a.m. CT

Room 278-282

**Session: 301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Thrombosis and the Endothelium**

**688: Elevated Levels of Low Density Lipoprotein (LDL) Trigger VWF Self-Association into Fibers and Bundles and Potentiate Microvascular Thrombosis**

Junmei Chen, Ph.D.

11:15 a.m. CT

Room 293-294

**Session: 321. Coagulation and Fibrinolysis: Basic and Translational II**

**694: Identification of Critical Proteins Required for Efficient Von Willebrand Factor Secretion Using CRISPR Knockout Screening**

Lauren Shevell, M.D.

11:15 a.m. CT

Room 291-292

**Session: 321. Coagulation and Fibrinolysis: Basic and Translational II**

**695: Sex-Specific Differences in the Pathogenesis, Endothelial Dysfunction, and Hypercoagulability of Sars-Cov-2 Infection in K18-hACE2 Mice**

Roberto Aiolfi, Ph.D.

11:30 a.m. CT

Room 291-292

**Session: 301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Thrombosis and the Endothelium**

**690: Targeting Activated Neutrophils in Antiphospholipid Antibody-Mediated Thrombosis**

Lin Di

11:45 a.m. CT

Room 293-294

**Session: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Frontline and Maintenance**

**714 Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (NCI9706 protocol; REMAIN Trial)**

Hongtao Liu, M.D., Ph.D.

11:45 a.m. CT

Room not yet listed

**Session: 114. Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Women's and Clinical Issues**

**805: Hormonal Contraceptive Use and Association with Thromboembolism in Women with Sickle Cell Disease**

Natasha Bala, M.D.

2:45 p.m. CT

Room 278-282

**Session: 114. Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Women's and Clinical Issues**

**806: Sickle Cell Disease-Specific Blood Pressure Thresholds for Hypertensive Disorders of Pregnancy: A Multinational Study**

Macy Early

3 p.m. CT

Room 278-282

**Session: 301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Mechanistic Insights That Suggest Novel Diagnostic or Therapeutic Strategies**

**812: Role of Glycogen Mobilization and Mitochondrial Bioenergetics in Platelet Function, Hemostasis, and Thrombosis**

Shravani Prakhya, M.S.

3 p.m. CT

Room 353-355

**Session: 301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Mechanistic Insights That Suggest Novel Diagnostic or Therapeutic Strategies**

**811: "Autoimmune HIT", a Potential Diagnostic Artifact Due to Remnant Heparin in HIT Samples, Is Not Associated with More Severe Outcomes**

Adam Kanack

3:15 p.m. CT

Room 353-355

**Session: 301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Mechanistic Insights That Suggest Novel Diagnostic or Therapeutic Strategies**

**813: Platelet ERO1 $\alpha$  Is Crucial for Ca<sup>2+</sup> Mobilization and Platelet Activation in Atherothrombosis**

Vishwanath Jha, Ph.D.

3:15 p.m. CT

Room 353-355

**Session: 637. Myelodysplastic Syndromes – Clinical and Epidemiological I**

**855: Phase 1 Results of the First-in-Class CXCR1/2 Inhibitor SX-682 in Patients with Hypomethylating Agent Failure Myelodysplastic Syndromes**

David Sallman, M.D.

3:15 p.m. CT

Room 243-245

**Session: 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Basic and Developmental**

**819 Hematopoietic Flt3+ Multipotent Progenitors Are Organized in Discrete Functionally and Hierarchically Distinct Populations**

Damien Reynaud  
3:15 p.m. CT  
Room 252-254

**Session: 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Basic and Developmental**

**820: Cap-Independent Protein Translation in Hematopoiesis**

Michael Mazzola, B.S.  
3:30 p.m. CT  
Room 252-254

**Session: 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Basic and Developmental**

**822: Novel Evidence That Intracellular Complement Network (complosome) Is Expressed in Hematopoietic Stem Cells (HSPCs) and Regulates Their Trafficking, Metabolism, and Proliferation in an Intracrine-Dependent Manner By Engaging Pattern Recognition Receptor Nlrp3 Inflammasome**

Vira Chumak, Ph.D.  
4 p.m. CT  
Room 252-254

**Session: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Immune Signaling and Antibody-therapeutic Targeting in Myeloid Neoplasms**

**931: IRAK1 Contributes to IRAK4 Inhibitor Resistance Via Non-Canonical Signaling Mechanisms in MDS/AML**

Josh Bennett, B.Sc.  
4:30 p.m. CT  
Room 353-355

**Special Session: AI and Machine Learning: A New Frontier in Hematology**

**AI in the Clinic: The Current Translation of Machine Learning Algorithms into Clinical Decision Tools**

Ilana Goldberg, Ph.D.  
4:30–6 p.m. CT

**Scientific Session: Session: Metabolic Regulation and Implications for Red Cells  
Regulation of Metabolism in Hematopoietic Differentiation**

Leonard I. Zon, M.D.  
4:30–5:45 p.m. CT  
Room not yet listed

**Special symposium on the basic science of hemostasis and thrombosis**

**Role of Factor XII in Sepsis**

Evi X. Stavrou, M.D.  
4:30–6:05 p.m. CT  
Room 208-210

**Session: 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Disease and Aging**

**923: Lasting Hematopoietic Memory Induced By Gestational Diabetes Contributes to Atherosclerosis Development in Adult Offspring**

Damien Reynaud

5:30 p.m. CT

Room 393-396

***Tuesday, December 13***

**Session: Late-Breaking Abstracts Session**

**LBA-4: Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703**

Shernan Holton, M.D. and Javier Bolanos-Meade, M.D.

9–10:30 a.m. CT

Hall E